NCT03085186No Longer Available不适用
Treatment With Crizotinib Single Patient Expanded Access IND 134375
Jean M. Tersak, M.D.0 个研究点开始时间: 2017年3月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
研究概览
简要总结
Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of abdomen.
Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more optimal tissue plains between vital structures prior to attempted surgical resection would greatly reduce potential morbidity for this patient.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 2 Years 至 2 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •This treatment plan is intended for the use of Crizotinib in the treatment of a single patient with Inflammatory Myofibroblastic Tumour
排除标准
- •Not applicable as Expanded Access only includes one patient
研究者
Jean M. Tersak, M.D.
Associate Professor
University of Pittsburgh
相似试验
招募中
不适用
A phase IB study of crizotinib in pediatric malignancieschildren, cancer, pediatric malignancies, ALK positive tumors, ROS1 positive tumors, MET positive tumorskinderen, kanker, pediatrische maligniteiten, tumoren positief voor ALK, ROS1, MET afwijkingenNL-OMON24969niversity Medical Center Erasmus Medical Center Rotterdam The Netherlands82
已完成
不适用
Phase II Study of Crizotinib in Japanese Patients with Advanced MET exon14 skipping mutation-positive or MET high gene copy number-positive non-small cell lung canceron-Small Cell Lung CancerJPRN-UMIN000031623ational Kyushu Cancer Center29
终止
2 期
Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform NeurofibromasPlexiform NeurofibromasNCT02177825St. Justine's Hospital5
终止
2 期
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial CancerUrethral NeoplasmsUreteral NeoplasmsUrinary Bladder NeoplasmsNCT02612194Wake Forest University Health Sciences8
已完成
1 期
A phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and phase I study of this drug for recurrent or refractory neuroblastomaRecurrent or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. Recurrent or refractory neuroblastomaJPRN-UMIN000028075St. Marianna University School of Medicine Hospital National Center for Child Health and Development Nagoya Medical Center Kyushu University Hospital23